ライフサイエンスコーパス: vaccination strategy

1 ially affect the efficacy of the current HBV vaccination strategy.

2 uld be a value as a potential universal mass vaccination strategy.

3 immunity and is ideal for a prime-and-boost vaccination strategy.

4 g an Ebola virus disease outbreak via a ring vaccination strategy.

5 NYVAC (rNYVAC) vector and Env protein boost vaccination strategy.

6 novel vaccine platform for a prime-and-boost vaccination strategy.

7 ng immunomodulating molecules is a promising vaccination strategy.

8 ronment would further enhance this promising vaccination strategy.

9 nts on clinical trial protocols using a ring-vaccination strategy.

10 asmodium sporozoites constitutes a promising vaccination strategy.

11 ct (HE) depends both on the HPV type and the vaccination strategy.

12 Ebola virus vaccine in the recommended ring vaccination strategy.

13 for the development of both therapeutic and vaccination strategies.

14 gladesh, to assess polio immunity and inform vaccination strategies.

15 ited as adjuvants for future therapeutic and vaccination strategies.

16 alian host, in particular with regard to BCG vaccination strategies.

17 us, it should be considered in future T cell-vaccination strategies.

18 should be considered for optimizing current vaccination strategies.

19 hat might benefit the rational design of new vaccination strategies.

20 children younger than 5 years of age in all vaccination strategies.

21 h into mechanisms of TPT, overwintering, and vaccination strategies.

22 nfections that are highly evasive to current vaccination strategies.

23 ity maturation, we studied a wide variety of vaccination strategies.

24 s a priority for implementing evidence-based vaccination strategies.

25 romising technological platform for improved vaccination strategies.

26 olecular adjuvants using DNA and DNA-protein vaccination strategies.

27 these antibodies are providing insights for vaccination strategies.

28 evaluate the protective potential of future vaccination strategies.

29 erlooked in the design and implementation of vaccination strategies.

30 interest in harnessing Tfh cells to improve vaccination strategies.

31 l responses, with important implications for vaccination strategies.

32 f adaptive immunity and an important goal of vaccination strategies.

33 d their potential role in improved influenza-vaccination strategies.

34 ection, and the development of novel mucosal vaccination strategies.

35 are generated will inform of ways to improve vaccination strategies.

36 e epidemiology and may inform genotyping and vaccination strategies.

37 rmining the feasibility and benefits of MenA vaccination strategies.

38 epidemiology, as well as to evaluate future vaccination strategies.

39 immune parameter for the evaluation of novel vaccination strategies.

40 this model to explore the impact of various vaccination strategies.

41 understanding of vaccine-induced immunity in vaccination strategies.

42 e valuable insights for future T(CD8+)-based vaccination strategies.

43 devise more effective adjunct treatment and vaccination strategies.

44 d may be employed for the design of improved vaccination strategies.

45 our antigens usually limit the efficiency of vaccination strategies.

46 eered CD8(+) T cells, as well as for peptide vaccination strategies.

47 disease and are important for peptide-based vaccination strategies.

48 at vaccination, will be key to defining CMV vaccination strategies.

49 olera transmission model to assess different vaccination strategies.

50 ortant implications for the design of future vaccination strategies.

51 ations for the development of more effective vaccination strategies.

52 ical observations, and have implications for vaccination strategies.

53 f T cell responses and a promising target in vaccination strategies.

54 potentially be modulated in support of novel vaccination strategies.

55 for the development of improved vaccines or vaccination strategies.

56 ct that could greatly affect the efficacy of vaccination strategies.

57 als and will help the design of future nasal vaccination strategies.

58 gy could inform the development of effective vaccination strategies.

59 need to know the potential economic value of vaccination strategies.

60 , and their generation is a key objective of vaccination strategies.

61 screening for cervical cancer and inform HPV vaccination strategies.

62 or improved vaccine development and informed vaccination strategies.

63 sidered in the design of dengue vaccines and vaccination strategies.

64 mportant proxy for determining potential RSV vaccination strategies.

65 ng epidemiologic trends and informing future vaccination strategies.

66 profiles (TPPs) for such vaccines and future vaccination strategies.

67 romising candidates to develop new effective vaccination strategies.

68 from sub-Saharan Africa are needed to inform vaccination strategies.

69 d economic outcomes under vaccination and no-vaccination strategies.

70 velopment of improved influenza vaccines and vaccination strategies.

71 the development of different candidates and vaccination strategies.

72 flexible context-specific dose regimens and vaccination strategies.

73 vantages of a diversity of anti-pneumococcal vaccination strategies.

74 cell response may successfully guide subunit vaccination strategies.

75 d to define sites of vulnerability and guide vaccination strategies.

76 and significantly contributes to prevention (vaccination) strategies.

77 e important implications for therapeutic and vaccination strategies against bacterial infection.

78 The development of effective vaccination strategies against dengue virus (DENV) infec

79 nity.IMPORTANCE The development of effective vaccination strategies against dengue virus infection is

80 his polymorphism may be relevant for peptide vaccination strategies against HCV infection.

81 Prime-boost vaccination strategies against HIV-1 often include multi

82 ofound implications for a transition to mass vaccination strategies against human influenza, and for

83 s may have important implications for future vaccination strategies against influenza.

84 es are likely to play complementary roles in vaccination strategies against influenza: in this contex

85 rferi infection would further development of vaccination strategies against Lyme disease.

86 Improved vaccination strategies against tuberculosis are needed,

87 d whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis.

88 delivery of LJM11 by Listeria is a promising vaccination strategy against cutaneous leishmaniasis ind

89 This study presents a new efficient vaccination strategy against henipaviruses and opens nov

90 These results reveal a promising vaccination strategy against herpes simplex virus 2, and

91 n of M158 Moreover, our results suggest that vaccination strategies aimed at generating broad protect

92 utralizer provides the opportunity to design vaccination strategies aimed at generating similar bNAbs

93 itic cells (DDCs) is a rational approach for vaccination strategies aimed at improving humoral immune

94 +) DDCs is therefore a rational approach for vaccination strategies aimed at improving humoral respon

95 ortant implications for the design of future vaccination strategies aimed at increasing the number of

96 that resemble the native Env are utilized in vaccination strategies aimed at inducing broadly neutral

97 This function can be harnessed for improving vaccination strategies aimed at inducing CTL.

98 to other tumor antigens and are relevant for vaccination strategies aimed to induce long-term antibod

99 ave major implications for the design of new vaccination strategies and adoptive immunotherapies.

100 d reconstitution may improve the efficacy of vaccination strategies and adoptive immunotherapy.

101 ideration of alternative maternally targeted vaccination strategies and can inform development of out

102 ults may have implications for the design of vaccination strategies and could lead to improvement of

103 Vaccination strategies and effectiveness estimates were

104 d the impact of current and potential future vaccination strategies and explored the potential trade-

105 ector cell activation, with implications for vaccination strategies and immunotherapeutic approaches.

106 Current rotavirus infant vaccination strategies and indirect protection of unvacc

107 es nontoxic PSMalpha3 derivatives for active vaccination strategies and lays the foundation for futur

108 lp to evaluate and direct current and future vaccination strategies and offer opportunities for novel

109 ve the potential to have an impact on future vaccination strategies and our understanding of the role

110 teritis would facilitate rapid assessment of vaccination strategies and the next generation of rotavi

111 This concept has the potential to transform vaccination strategies and usher in a new approach to im

112 We discuss different vaccination strategies and we highlight challenges facin

113 placement (cohort) and lifetime (continuous) vaccination strategies, and applied it to a Salmonella C

114 ctiveness of alternative maternally targeted vaccination strategies (antenatal delivery vs. postnatal

115 milar to the estimated costs of the reactive vaccination strategy (approximately 10 million US dollar

116 ts the need for improved surveillance before vaccination strategies are designed.

117 Influenza virus vaccination strategies are focused upon the elicitation

118 Numerous neoepitope-based vaccination strategies are in testing for clinical use i

119 New vaccination strategies are needed to control infections

120 d full-length HAs, confirming that cHA-based vaccination strategies are superior at generating stalk-

121 Improved vaccination strategies are urgently needed to curb the g

122 No effective treatment or vaccination strategies are yet available.

123 either as monotherapy or in conjunction with vaccination strategies, are reviewed.

124 re, the potential of phosphorylcholine-based vaccination strategies as a novel tool for the preventio

125 ing peptide that may be harnessed as a novel vaccination strategy as well as a therapeutics delivery

126 Vaccination strategies based on catch-up vaccination of

127 ratory models of tuberculosis has shown that vaccination strategies based on heterologous prime-boost

128 portant considerations in the development of vaccination strategies based on live-attenuated viruses.

129 e report a novel universal influenza B virus vaccination strategy based on "mosaic" hemagglutinins.

130 A vaccination strategy based on chimeric hemagglutinin (cH

131 s work reports a universal influenza B virus vaccination strategy based on focusing antibody response

132 We also describe an antibacterial vaccination strategy based on immunization with the glyc

133 Here, we demonstrate that a vaccination strategy based on the stalk domain of the H3

134 antigen expression along with a therapeutic vaccination strategy, but not knockdown alone, increased

135 In this article, we have developed a vaccination strategy by targeting protein Ags to B cells

136 These findings suggest that systemic vaccination strategies can elicit potentially important

137 Therefore, Env protein-based vaccination strategies can protect against hard-to-neutr

138 This paper is based on the idea that vaccination strategies can serve as a method to identify

139 INTERPRETATION: The results show that a ring vaccination strategy can be rapidly and safely implement

140 e the impact of 3 alternative district-level vaccination strategies, compared with that currently use

141 tudy, we employed a heterologous prime-boost vaccination strategy comprising intradermally administer

142 Effective vaccination strategies could help to address many challe

143 An effective RSV vaccination strategy could have a major impact on the bu

144 Switching to a wP-priming vaccination strategy could reduce whooping cough inciden

145 issue of Immunity, Chen et al. propose a new vaccination strategy, demonstrating that Th17 memory cel

146 There were many developments to improve vaccination strategies, demonstration of new molecules i

147 Vaccination strategies designed to elicit durable cellul

148 The effectiveness of all the vaccination strategies drops off as the timing is delaye

149 The combined vaccination strategy elicited both antigen-specific T-ce

150 s lives before it was eradicated by a simple vaccination strategy: epicutaneous application of the re

151 These results further suggest that vaccination strategies focused on the development of cro

152 owever, numerous clinical trials are testing vaccination strategies for AD, suggesting that T and B c

153 and from the PCV13 era are needed to inform vaccination strategies for elderly adults.

154 t supply and little is known about effective vaccination strategies for epidemic cholera.

155 The development of autoantigen-specific vaccination strategies for Foxp3(+)Treg-induction and pr

156 rk has significant implications for improved vaccination strategies for future influenza pandemics.

157 These results suggest that novel vaccination strategies for high-risk groups, including t

158 viously used in the United Kingdom to inform vaccination strategies for influenza, with extensions to

159 Optimal hepatitis B (HBV) vaccination strategies for lung transplantation (LT) can

160 ns of augmenting the immune response both in vaccination strategies for microbial infections and in t

161 n of polio and development of more effective vaccination strategies for other pathogens.

162 these studies suggest previously unexplored vaccination strategies for pathogen-associated antigens

163 ese findings introduce previously unexplored vaccination strategies for pathogens that target the B-1

164 We also summarize infection control and vaccination strategies for patients, family members, and

165 Livestock vaccination strategies for the region should include bot

166 ate goal of designing novel patient-specific vaccination strategies for the treatment of FL.

167 and may support the development of novel DC vaccination strategies for transplantations, as well as

168 t show promise for informing therapeutic and vaccination strategies for vulnerable patients.

169 We evaluated the following adult vaccination strategies for women only and for both women

170 NA approach appears to represent a promising vaccination strategy for CHIK and other alphaviral disea

171 veloped a promising heterologous prime-boost vaccination strategy for EBV-associated malignancies and

172 alth structures to implement a screening and vaccination strategy for HCWs.

173 port further evaluation of this modified BCG vaccination strategy for HIV-exposed infants.

174 ped and previously reported on a therapeutic vaccination strategy for indolent B-cell lymphoma that c

175 lineage and HIV-1 co-evolution to suggest a vaccination strategy for inducing both lineages.

176 of population-level immunity and the optimal vaccination strategy for long-term control of MenA menin

177 ecision makers on maternal immunization as a vaccination strategy for protection of young infants aga

178 use model, offering a promising translatable vaccination strategy for the functional cure of chronic

179 restoration of Ag-specific tolerance through vaccination strategies, for example in type 1 diabetes p

180 cquired immunity could benefit the design of vaccination strategies, for example those aimed at elici

181 The rMVA-tmIgE antitumor vaccination strategy has been investigated in FcepsilonR

182 Influenza vaccination strategies have targeted elderly individuals

183 Thus, the LVS DeltacapB-rLm/iglC prime-boost vaccination strategy holds substantial promise for a vac

184 iability of assessments of outbreak risk and vaccination strategy impact in emergency settings.

185 defining HAdV-based vector manufacturing and vaccination strategies.IMPORTANCE Adenovirus-based vecto

186 nclusion of multiple variants in prime-boost vaccination strategies improves recognition of variant v

187 the potential effectiveness of age-specific vaccination strategies in averting RSV incidence, we dev

188 o estimate the economic impact of a range of vaccination strategies in Burkina Faso.

189 er and warrants consideration of therapeutic vaccination strategies in combination with PD-1 blockade

190 rations for universal, risk-based, or phased vaccination strategies in different settings.

191 nd suggest a broad counterintuitive role for vaccination strategies in mitigating undesirable immune

192 ave important implications for the design of vaccination strategies in neoplastic or chronic infectio

193 help plan vaccination campaigns and transit vaccination strategies in Pakistan.

194 mplications for the timing of future malaria vaccination strategies in pregnant women.

195 a suitable priming immunogen for sequential vaccination strategies in the context of polyclonal repe

196 luated a multivalent live-attenuated mucosal vaccination strategy in a murine model of acute P. aerug

197 Here we set out to test this vaccination strategy in the ferret model.

198 d vaccines are yet available, but in a trial vaccination strategy in West Africa, recombinant, infect

199 the findings were instrumental in optimizing vaccination strategy in western Uttar Pradesh with respe

200 then compared the impact of a mine-targeted vaccination strategy, in which miners were vaccinated wh

201 udies are needed to determine whether a ring vaccination strategy, in which vaccine is given quickly

202 erize the impact and trade-offs of potential vaccination strategies, including the introduction of in

203 New vaccination strategies incorporating NA, including PIV5-

204 In conclusion, our DC vaccination strategy induced or expanded a CMV-specific

205 ovide critical information for the design of vaccination strategies intended to provoke cell-mediated

206 ) would be improved when incorporating these vaccination strategies into the DNA priming phase, as de

207 Developing new adjuvants and vaccination strategies is of paramount importance to suc

208 ariants for a given immunogen in prime-boost vaccination strategies is one approach that aims to impr

209 This vaccination strategy is effective at generating HA stalk

210 Our in situ vaccination strategy is feasible also in MF and the clin

211 A seasonal vaccination strategy is likely to provide the most direc

212 -29 years of age, the most effective modeled vaccination strategy is to conduct mass vaccination camp

213 For safety reasons, human vaccination strategies largely use attenuated nonreplica

214 These data suggest that mucosal pneumococcal vaccination strategies may be important for vulnerable p

215 V-A16 and EV-A71 and we explore what spatial vaccination strategies may best reduce the burden of HFM

216 et of epidemic, during which the outcomes of vaccination strategies may differ significantly and are

217 This vaccination strategy might be developed as a neoadjuvant

218 erd effects might render a year-round infant vaccination strategy more appealing, although it is curr

219 otal number of memory cells, indicating that vaccination strategies need to consider this issue.

220 PLs could improve the therapeutic outcome of vaccination strategies or can be used for ex vivo enrich

221 An analysis of vaccination strategies over time highlights the transiti

222 population-based, but also more personalized vaccination strategies ('precision vaccination').

223 demonstrate for the first time that an oral vaccination strategy prevents Pneumocystis infection.

224 Current vaccination strategies prioritizing elderly persons may

225 We show that prime-boost vaccination strategies provide protection against both l

226 Alternative vaccination strategies should also be studied.

227 Universal influenza vaccination strategies should be capable of protecting a

228 tes of the relative performance of different vaccination strategies should be robust to these factors

229 Novel anti-HCV vaccination strategies should target the induction of TL

230 Optimal YF vaccination strategy should be tailored to the risk prof

231 Deploying this as a cell-based vaccination strategy showed efficacy in both prophylacti

232 Under the best assumptions, optimal vaccination strategies substantially reduced the illness

233 will allow for an exploration of alternative vaccination strategies such as different age-spacings, f

234 New vaccination strategies, such as increased vaccine dose,

235 not as efficient as many other potential HPV vaccination strategies, such as increasing primary 9vHPV

236 the development of antimicrobial therapies, vaccination strategies, targeted public health measures,

237 However, sustainable and effective vaccination strategies targeting adults are still lackin

238 o, and imply that more effective therapeutic vaccination strategies targeting CD8+ Tcm in patients on

239 rstanding initiation of immune responses and vaccination strategies targeting DCs and activated monoc

240 mpartmentalization is valuable for designing vaccination strategies targeting distal mucosae.

241 These results suggest that vaccination strategies targeting the ICOS and Bcl6 pathw

242 enicity of rSeV-based vaccines, but all four vaccination strategies tested resulted in complete prote

243 In this article, we describe a novel vaccination strategy, tested preclinically in mice, for

244 they recognize the virus, and we discuss new vaccination strategies that aim to mimic natural evoluti

245 rates and evaluate the outcomes of different vaccination strategies that are influenced by the level

246 oal of AIDS vaccine development is to design vaccination strategies that can elicit broad and potent

247 e way for the development of next-generation vaccination strategies that completely prevent malaria.

248 tant implications for the design of maternal vaccination strategies that could synergize with ART dur

249 elopment of recombinant and vectored subunit vaccination strategies that have, however, not yet match

250 Influenza A(H5N1) vaccination strategies that improve the speed of the imm

251 exploration of the MV1-F4 vector modality in vaccination strategies that may limit HIV-1 infectivity.

252 ramework for improved design of age-specific vaccination strategies that require further evaluation i

253 T-2 adapters, our results suggest that human vaccination strategies that specifically facilitate SLAM

254 ugh the peripheral tissues and highlight new vaccination strategies that take advantage of this newly

255 ysis of a PCV trial can assist in developing vaccination strategies that target specific geographic s

256 ting susceptible hosts and in development of vaccination strategies that will poise most human subjec

257 up the possibility for microneedle-based HIV vaccination strategies that, once fully developed, will

258 ay allow the development of an efficient HIV vaccination strategy that is capable of inducing both ro

259 cles, or dense bodies, may constitute a safe vaccination strategy that mimics natural infection.

260 th an urgent need for new and more efficient vaccination strategies, the integration of these data wi

261 populations and thus improve forecasting and vaccination strategies to combat seasonal influenza.

262 Within this context, we discuss vaccination strategies to elicit broad and potent immune

263 ble public health interest in developing new vaccination strategies to improve control of pertussis.

264 Better vaccination strategies to improve response rate are need

265 f countries to implement maternally targeted vaccination strategies to protect vulnerable infants, bu

266 The optimal long-term vaccination strategies to provide population-level prote

267 ces and will help policy makers to formulate vaccination strategies to reduce the burden of severely

268 DCs present a promising cellular target for vaccination strategies to resolve chronic liver infectio

269 In this study, we used an aerosol vaccination strategy to administer AERAS-402, a replicat

270 ous prime-boost may provide a more effective vaccination strategy to broaden the antibody responses t

271 of NY-ESO-1 to APC appears to be a promising vaccination strategy to efficiently generate integrated

272 ion peptide, it may be possible to develop a vaccination strategy to induce these CD4(+) T cells, whi

273 Development of a more effective vaccination strategy to prevent pulmonary TB, the most c

274 90% during 2018-2030, by comparing realistic vaccination strategies under a range of scenarios of vac

275 odel, we searched for cost-effective booster vaccination strategies using a genetic algorithm.

276 A prime-boost intranasal vaccination strategy using TBI in the context of a bcmd-

277 ims to compare the impact of alternative HPV vaccination strategies, using data from Sweden, a high-i

278 To that end, we establish a vaccination strategy utilizing membrane vesicles derived

279 scuss the new data and mainly considered two vaccination strategies: vaccination of populations with

280 This vaccination strategy was also optimal in 48 countries as

281 The qHPV vaccination strategy was cost saving; it decreased lifet

282 Our data shows that a prime-boost vaccination strategy was effective in eradicating 3LL lu

283 The future disease burden for each vaccination strategy was predicted using a dynamic trans

284 d Gram-positive bacteria-dendritic cell (DC) vaccination strategy, we determined that in vivo depleti

285 Six antiviral vaccination strategies were evaluated to generate traini

286 All vaccination strategies were found to be preferable to a

287 Using a total of 28 baboons, different vaccination strategies were used including recombinant S

288 ated with live P. murina using a prime-boost vaccination strategy were protected from a subsequent lu

289 n together, our findings provide a potential vaccination strategy where heterologous influenza immuni

290 g the first 10 years after the start of each vaccination strategy, whereas the existing program yield

291 Second, I describe a passive vaccination strategy whereby recombinant adeno-associate

292 e modified vaccinia virus Ankara (MVA)-boost vaccination strategy, which uses mismatched Gag immunoge

293 Improved vaccination strategies will be needed to drive persisten

294 Our findings suggest that different vaccination strategies will be required to optimize prot

295 Using more effective vaccines and vaccination strategies will increase population immunity

296 ave major implications for the design of new vaccination strategies with adoptive T cell therapy.

297 inform policy recommendations for long-term vaccination strategies with MenAfriVac.

298 the community-randomized trial results about vaccination strategy with mathematical modeling to asses

299 Regional-specific influenza vaccination strategies would be optimal in China; in par

300 A convenient but more immunogenic vaccination strategy would enhance vaccine performance,